EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2025

  • ID: 4032600
  • Drug Pipelines
  • 55 pages
  • GlobalData
1 of 4
Colorectal cancer (CRC) is a cancer that starts in the colon or the rectum (ACS, 2016). CRC is one of the most common types of cancers diagnosed; it is the third most common cancer among men and the second most common in women, worldwide (Ferlay et al., 2016). CRC is a high-mortality cancer, with mortality rates just behind lung, liver, and stomach cancers in men, and breast and lung cancers in women.

In 2015, there were 746,590 diagnosed incident cases of CRC in the 8MM. Epidemiologists forecast that the diagnosed incident cases in the 8MM will increase to 913,832 by 2025 at an Annual Growth Rate (AGR) of 2.24%. With the exception of the US and Germany, all markets will see an increase in the number of cases, at varying AGRs. The 8MM combined had an estimated 2,582,288 five-year diagnosed prevalent cases of CRC in 2015. The number of five-year diagnosed prevalent cases will increase by 22.06% over the next 10 years to 3,151,930 by 2025.

Urban China will have the highest number of diagnosed incident and five-year diagnosed prevalent cases among the 8MM, as well as the highest AGR for both data types. The US and Germany are the only markets that will see a decrease in incidence rate during the forecast period.

Worldwide, CRC is the third most common cancer in men and the second most common cancer in women (Ferlay et al., 2016). Estimates show that almost 55% of CRC cases are diagnosed in more developed regions (Ferlay et al., 2016). CRC has a strong relationship with age, and it is most commonly diagnosed in patients older than 65 years (Erichsen et al., 2013; Jørgensen et al., 2012). In 2012, CRC accounted for almost 10% of the global cancer incidence burden (Stewart and Wild, 2014). A study examining the global trends of CRC analyzed data from 51 cancer registries around the world and found that incidence of CRC increased significantly in countries going through an economic transition such as those found in Eastern Europe, most parts of Asia, and certain parts of South America (Center et al., 2009b).

The report “EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2025” provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast of the diagnosed incident cases and the five-year diagnosed prevalent cases of CRC in these markets from 2015-2025.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1.1 List of Tables

1.2 List of Figures

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global Trends

2.3.1 8MM Incidence Trends

2.3.2 8MM, Trends in Five-Year Relative Survival

2.4 Forecast Methodology

2.4.1 Sources Used Tables

2.4.2 Forecast Assumptions and Methods

2.4.3 Sources Not Used

2.5 Epidemiological Forecast for CRC (2015-2025)

2.5.1 Diagnosed Incident Cases of CRC

2.5.2 Age-Specific Diagnosed Incident Cases of CRC

2.5.3 Sex-Specific Diagnosed Incident Cases of CRC

2.5.4 Age-Standardized Diagnosed Incidence of CRC

2.5.5 Diagnosed Incident Cases of CRC by Stage at Diagnosis

2.5.6 Type of Genetic Mutation among Diagnosed Incident Cases of CRC

2.5.7 Five-Year Diagnosed Prevalent Cases of CRC

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 Limitations of the Analysis

2.6.3 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologists

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.3 About the Author

3.4 About EpiCast

3.5 Disclaimer

1.1 List of Tables

Table 1: Risk Factors and Comorbidities For CRC

Table 2: 8MM, Five-Year Relative Survival (%)

Table 3: 8MM, Sources Used to Forecast the Diagnosed Incidence of CRC

Table 4: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CRC

Table 5: 8MM, Sources of CRC Cancer Stage at Diagnosis

Table 6: 8MM, Sources of Genetic Mutations

Table 7: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages =18 Years, 2015-2025

Table 8: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Row (%), 2015

Table 9: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages =18 Years, Row (%), 2015

Table 10: 8MM, Diagnosed Incident Cases of CRC by Cancer Stage at Diagnosis (N), Ages =18 Years, Row (%), 2015

Table 11: 8MM, Diagnosed Incident Cases of CRC by Type of Genetic Mutation (N), Both Sexes, Ages =18 Years, 2015

Table 12: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages =18 Years, 2015-2025

1.2 List of Figures

Figure 1: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Men, Ages =15 Years, 1998-2007

Figure 2: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Women, Ages =15 Years, 1998-2007

Figure 3: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages =18 Years, 2015-2025

Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Ages =18 Years, 2015

Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages =18 Years, 2015

Figure 6: 8MM, Age-Standardized Incidence of CRC (Cases per 100,000 Population), Ages =18 Years, by Sex, 2015.

Figure 7: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages =18 Years, 2015-2025
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll